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Abstract
AIM: To investigate treatment outcome of Helicobacter 
pylori  (H. pylori )-negative low-grade gastric mucosa-
associated lymphoid tissue (MALT) lymphoma. 
METHODS: In this study, we retrospectively reviewed 
the clinical outcome and clinicopathologic factors of 
stage ⅠE H. pylori -negative low-grade gastric MALT 
lymphoma cases from August 1998 to June 2009. 
RESULTS: A total of eleven patients with H. pylori -neg-
ative low-grade gastric MALT lymphoma were enrolled 
in the study and received anti-H. pylori  eradication 
treatment and/or radiotherapy or excisional therapy. 
Complete remission (CR) of gastric MALT lymphoma was 
achieved in all patients. The time to CR was 1-66 mo 
(median, 1 mo).
CONCLUSION: Eradication therapy may be offered as 
an initial treatment option even in cases of localized 
H. pylori -negative gastric MALT lymphoma. 
© 2010 Baishideng. All rights reserved.
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INTRODUCTION
Mucosa-associated lymphoid tissue (MALT) lymphoma, 
first described in 1983 by Isaacson and Wright[1], has been 
recently re-classified as extranodal marginal zone lympho-
ma of  MALT-type, in the Revised European-American 
Classification of  Lymphoid Neoplasms (REAL)/World 
Health Organization (WHO) Classification of  Lymphoid 
Neoplasms. An important feature of  MALT lymphoma 
is the presence of  lymphoepithelial lesions formed by the 
invasion of  individual glands by aggregates of  lymphoma 
cells[2]. 
In previous studies, Helicobacter pylori (H. pylori) infection 
was suggested to be causally associated with primary gastric 
MALT lymphoma[3,4]. Indeed, H. pylori provides the antigen-
ic stimulus, which is mediated by mucosal T cells, for susta-
ining the growth of  gastric MALT lymphoma[5]. The regre-
ssion of  gastric MALT lymphoma after the eradication of  
H. pylori was first reported in 1993 by Wotherspoon et al[3]. 
H. pylori eradication led to complete remission in 80% of  
stage ⅠE, low-grade gastric MALT lymphoma patients, 
with a yearly recurrence rate of  approximately 5%[6]. Curr-
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ently, eradication of  H. pylori is considered the accepted ini-
tial therapy in cases of  localized, stage ⅠE low-grade gastric 
MALT lymphoma[7]. 
However, there are no treatment guidelines for the 
management of  patients who are unresponsive to antibi-
otic treatment or for the subset of  patients who present 
with stage ⅠE low-grade gastric MALT lymphoma but are 
H. pylori-negative and understandably do not respond to 
antibiotic treatment[8]. In these cases, treatment choices 
include the known, conventional therapeutic approaches 
such as surgery, chemotherapy or radiotherapy[9]. Because 
of  the ambiguity of  treatment in H. pylori-negative patients, 
further studies are required to clarify a treatment strategy 
for H. pylori-negative MALT lymphoma. In this study, we 
evaluated the treatment outcome of  eleven H. pylori-nega-
tive low-grade gastric MALT lymphoma patients to offer 
therapeutic guidelines for treating H. pylori-negative low-
grade gastric MALT lymphoma. 
MATERIALS AND METHODS
Patients
We retrospectively studied eleven patients with H. pylori-
negative low-grade gastric MALT lymphoma diagnosed at 
the Severance Hospital from August 1998 to June 2009. 
All patients were confirmed by pathology to have low-
grade gastric MALT lymphoma without a diffuse large 
B-cell lymphoma (DLBCL) component. Histological 
diagnosis of  MALT lymphoma was performed accord-
ing to the criteria outlined in the WHO classification, and 
histological assessment was performed by a reference 
pathologist (Yang WI). Immunological phenotyping of  
paraffin sections was performed to demonstrate light chain 
restriction and the CD20+CD5-CD10-cyclinD1- phenotype 
which was microscopically consistent with the presence of  
low-grade MALT lymphoma. The study was approved by 
our institutional review board, and informed consent was 
not required.
Examination of H. pylori infection and endoscopic 
findings 
None of  the patients had evidence of  H. pylori infection as 
judged by histology, a urea breath test, a rapid urease test 
(CLOTM, Delta West, Bentley, Western Austria) and sero-
logical testing. The gross phenotype for each patient was 
classified into five types according to endoscopic features: 
(1) ulcerative: one or more ulcerations; (2) protruding: 
elevated or polypoid; (3) granular: small nodules on the le-
sion; (4) infiltrative: mucosal infiltration; and (5) mixed.
Staging work-up 
Determination of  the stage of  disease included a de-
tailed physical examination, chest X-ray, abdominal com-
puted tomography (CT), endoscopic ultrasonography 
(EUS), bilateral bone marrow examination, and 18F-FDG 
PET scan.
Therapeutic approach
Treatment modalities included anti-H. pylori eradica-
tion therapy, radiotherapy, and excisional therapy (one 
endoscopic mucosal resection and one subtotal gastre-
ctomy). The most common treatment was radiotherapy 
(six patients), followed by anti-H. pylori eradication only 
(three patients). Prior to radiotherapy, three of  the six 
radiotherapy patients received anti-H. pylori eradication 
therapy which consisted of  amoxicillin (2 × 1000 mg/d), 
clarithromycin (2 × 500 mg/d), and esomeprazole (2 
× 40 mg/d) or pantoprazole (2 × 20 mg/d) for 7 or 
14 d. Radiotherapy was performed at a total dose rang-
ing from 30 Gy to 36 Gy on an outpatient basis. Two 
patients underwent local excision therapy, including one 
subtotal gastrectomy and one endoscopic mucosal resec-
tion (EMR). 
Response assessment 
The median time for follow-up after remission was 25 mo 
(range: 5-76 mo). Complete remission (CR) was defined as 
the total disappearance of  clinical evidence for lymphoma 
and an absence of  histologic evidence for lymphoma on 
biopsy specimens. Partial remission (PR) was defined as a 
tumor reduction of  at least 50%, and stable disease (SD) 
was defined as variation within either a 50% decrease or 
25% increase in tumor size. In cases with complete remis-
sion, endoscopic examinations and biopsies were per-
formed at regular intervals. 
RESULTS
Baseline characteristics
The male to female patient ratio in this study was 1:1.2. 
The mean age of  the patients was 55.7 (36-73) years. 
Four patients were symptomatic at presentation indicat-
ing abdominal pain (two cases), abdominal discomfort 
(one case), and GI bleeding (one case). Lymphoma was 
most often localized in the body and the antrum in 36% 
of  the patients. Endoscopic lesions were characterized as 
ulcerative (five cases), infiltrative (one case), protruding 
(two cases), granular (one case) and mixed (two cases). 
Initial endoscopic findings are summarized in Table 1. 
Initial clinical staging with EUS and/or CT scans and BM 
examinations revealed all the cases to be stage ⅠE.
Treatment outcome
Complete remission (CR) of  gastric MALT lymphoma was 
achieved in all patients (Table 2). The time to CR ranged 
from one to 66 mo (median, 1 mo). Anti-H. pylori eradica-
tion therapy was performed in six of  the eleven patients. 
Three of  six patients, who completed the follow-up endo-
scopic examination 1 or 2 mo later, had complete remis-
sion of  gastric MALT lymphoma. However, two patients 
refused to wait for the treatment response evaluation and 
subsequently underwent radiotherapy for definitive treat-
ment. The remaining patient had stable disease for 2 mo 
before being referred for radiotherapy. All three of  these 
patients showed complete remission of  gastric MALT 
lymphoma 1 mo after the cessation of  radiotherapy based 
on histological evidence. None of  the 11 patients showed 
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local or distant recurrence after a median follow-up time 
of  25 mo (range: 5-76 mo). 
DISCUSSION
The prevalence of H. pylori in patients with low-grade 
gastric MALT lymphoma is variable[10]. It is possible 
that a reduced number of  H. pylori organisms present 
in the infection may account for the negative H. pylori 
diagnostic test result in some cases, and false-negative 
results may also be obtained when only one diagnostic 
method is employed[11]. The European Guidelines gener-
ally take the gold standard to be represented by at least 
two tests[12]. When appropriate diagnostic methods are 
used, the prevalence of  H. pylori infection in low-grade 
MALT lymphoma is high, at nearly 90%[10]. In our study, 
four diagnostic tests were performed and showed that 
true H. pylori-negative patients were included. However, 
additional tests, such as culture with polymerase chain 
reaction, would allow the detection and identification of  
other infective organism[13]. 
Due to the excellent clinical outcome of  H. pylori 
eradication treatment, the eradication of  H. pylori with 
antibiotics should be employed as the sole initial treatment 
in the localized form (confined to the stomach) of  gastric 
MALT lymphoma[14]. However, in advanced stages with 
H. pylori-positive gastric MALT lymphoma and in H. pylori-
negative lymphoma, definitive treatment guidelines are 
not yet available despite the numerous published clinical 
research papers[8,14,15]. 
Antibiotic treatment for H. pylori-negative gastric 
MALT lymphoma has been described in a limited num-
ber of  patients. We collectively reviewed a series of  four 
published studies including patients treated solely with the 
anti-H. pylori antibiotic regimen as the initial treatment for 
H. pylori-negative stage ⅠE gastric MALT lymphoma 
(Table 3). A total of  31 patients were included in these 
studies, and ten patients (32%) were shown to respond to 
this treatment alone. Raderer et al[16] reported that five of  
six patients with H. pylori-negative gastric MALT lympho-
ma responded to antibiotic treatment (one partial remis-
sion and four complete remissions). However, Steinbach 
et al[17] and Ye et al[18] experienced a 0% response rate. In 
other words, marked variation in treatment response rate 
was noted. Nevertheless, instituting anti-H. pylori treatment 
showed satisfactory clinical outcomes and allowed for 
gastric preservation in a significant number of  cases with 
H. pylori-negative gastric MALT lymphoma. Although 
seemingly contradictory, anti-H. pylori treatment may be 
advised as the first-line therapy in H. pylori-negative local-
ized gastric MALT lymphoma. Unfortunately, the effec-
tiveness of  anti-H. pylori treatment could not be confirmed 
in this study, as only four out of  the six patients who 
received the anti-H. pylori eradication regimen waited long 
enough to receive the follow-up endoscopic examination 
which was used to confirm the complete remission status 
of  MALT lymphoma. The other two patients proceeded 
to radiation therapy due to various clinical and psycho-
social issues. In addition, previous studies also included 
patients with advanced stages of  disease, including ⅡE1 
(Table 3). However, it was not possible from the avail-
able data to categorize lymphoma regression according to 
tumor stage (ⅠE vs ⅡE1). Therefore, additional studies 
are needed to define the role of  anti-H. pylori eradication 
therapy in advanced stages of  gastric MALT lymphoma 
such as stages ⅡE, ⅢE or Ⅳ. 
There is still no explanation for the effectiveness of  
anti-H. pylori treatment in H. pylori-negative gastric MALT 
lymphoma[16]. However, it has been speculated that an-
other infective organism, Helicobacter heilmannii[19], might be 
involved in the development of  gastric MALT lymphoma. 
Also, one cannot rule out the possibility that unknown 
bacterial agents capable of  surviving in the stomach might 
play a role in the development of  rare H. pylori-negative 
2160 May 7, 2010|Volume 16|Issue 17|WJG|www.wjgnet.com
Table 2  Individual characteristics of 11 cases of H. pylori -




Stage Treatment Response Time 
to CR
(mo)
Follow up time 
after remission 
(mo)
Case 1 54/F ⅠE Eradication CR   1   6
Case 2 60/F ⅠE Eradication CR   1 27
Case 3 52/F ⅠE Eradication CR   2 25
Case 4 36/M ⅠE RTx CR   1 76
Case 5 58/F ⅠE RTx CR   2 17
Case 6 69/M ⅠE RTx CR   1 47
Case 7 41/F ⅠE Eradication 
+ RTx
CR   1   7
Case 8 62/M ⅠE Eradication
+ RTx
CR   1   8
Case 9 55/M ⅠE Eradication
-> RTx
CR   1   5
Case 10 73/F ⅠE STG CR 66 54
Case 11 53/M ⅠE EMR CR   2 69
CR: Complete remission; RTx: Radiotherapy; STG: Subtotal gastrectomy; 
EMR: Endoscopic mucosal resection.
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Table 1  Baseline characteristics of H. pylori -negative low-
grade gastric MALT lymphoma  n  (%)
H. pylori  negative MALT lymphoma (n  = 11)
Age (yr, mean)    55.7 (36-73)
Sex
Men    5 (45)
Women    6 (55)
Site
Cardia  1 (9)
Fundus  1 (9)
Body only    3 (27)
Body & antrum    4 (36)
Diffuse    2 (18)
Endoscopy
Ulcerative    5 (45)
Infiltrative  1 (9)
Protruding    2 (18)
Granular  1 (9)
Mixed    2 (18)
H. pylori: Helicobacter pylori; MALT: Mucosa-associated lymphoid tissue.
gastric MALT lymphomas[16]. Another possibility is that 
low bacterial counts[20] and urease-negative H. pylori mu-
tant strains may escape detection by the diagnostic tests 
that are currently available. If  this assumption is correct, 
one might expect the noted H. pylori-negative gastric 
MALT lymphoma patient response to broad-spectrum an-
tibiotic therapy. Also, MALT lymphoma is to some extent 
an immunologically driven disease, therefore an additional 
hypothesis may involve the potential immunomodulatory 
effects of  the antibiotic agents used[16]. 
Disease control using radiotherapy alone has been 
previously reported in the literature, which supports the 
use of  a modest dose of  involved-field radiotherapy for 
patients with stages ⅠE-ⅡE MALT lymphoma of  the 
stomach without evidence of  H. pylori infection[14]. Table 4 
summarizes these previously reported cases. Including our 
cases, 35 of  35 cases responded to radiotherapy. One of  
the 35 patients reported by Akamatsu et al[21] had a partial 
remission, while the others all had a complete remission. 
Based on these results, it is prudent to say that radiothera-
py is suitable in early stage (ⅠE or ⅡE) H. pylori-negative 
gastric MALT lymphoma. In addition, excisional treat-
ments such as endoscopic mucosal resection or laparo-
scopic gastric resection may represent another therapeutic 
option in the case of  localized forms of  gastric MALT 
lymphoma in individuals who are not suitable for, or who 
refuse, standard therapeutic approaches[15,20,22]. In the past, 
surgical treatment has often been advocated to establish 
accurate diagnosis, staging, and management of  early-
stage gastric lymphoma, which has about a 90% 5-year 
survival rate, but leads to significant morbidity[22]. In our 
study, two patients received endoscopic mucosal resection 
and subtotal gastrectomy, respectively. There has been no 
local or distant recurrence during the follow-up period of  
54 to 69 mo. 
In our series, therapeutic measures such as anti-H. pylori 
eradication, radiotherapy and excisional therapy achieved 
complete remission in all cases. Nevertheless, antibiotic 
treatment is simple, inexpensive, less harmful and H. pylori 
negative low grade MALT lymphoma shows a favorable 
long-term outcome[22]. Therefore we suggest that H. pylori 
eradication therapy may be an initial treatment option 
for localized H. pylori-negative gastric MALT lymphoma. 
In addition, further studies on eradication therapy are 
required to help in the establishment of  strategies for pa-




Eradication of Helicobacter pylori (H. pylori) is a well-accepted initial therapy in 
cases of localized (stage ⅠE) low-grade gastric mucosa-associated lymphoid 
tissue (MALT) lymphoma associated with H. pylori infection. However, there are 
no treatment guidelines for the management of H. pylori-negative low-grade 
gastric MALT lymphoma.
Research frontiers
Previous studies revealed the effectiveness of radiotherapy for localized 
H. pylori-negative low grade gastric MALT lymphoma. However, H. pylori 
eradication therapy is still a controversial treatment modality, although this 
treatment is simple and less harmful than other treatments. 
Innovations and breakthroughs
With the exception of this study, only 31 H. pylori-negative patients have re-
ceived eradication therapy (response rate 32%). However, treatment response 
was variable. The authors’ study enrolled a small number of patients, but they 
all had complete remission. 
Applications 
The findings from this study suggest that H. pylori eradication therapy may be 
an initial treatment option for localized H. pylori-negative gastric MALT lympho-
ma. Their study adds information which helps in the establishment of strategies 
for patients with localized H. pylori-negative gastric MALT lymphoma.
Peer review
This is an interesting paper that may be beneficial for patients with H.pylori-
negative gastric MALT lymphoma. 
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